Full-Time
Confirmed live in the last 24 hours
Cloud-based platform for life sciences R&D
$100k - $152kAnnually
Senior, Expert
San Francisco, CA, USA
This is a hybrid position, which may require some in-office days.
You match the following Benchling's candidate preferences
Employers are more likely to interview you if you match these preferences:
Benchling provides a platform designed for life sciences research and development, primarily catering to biotech and pharmaceutical companies, academic institutions, and research organizations. Its cloud-based platform includes tools like an electronic lab notebook, molecular biology tools, and sample tracking systems, which help scientists manage experimental data, collaborate with colleagues, and streamline workflows. Users can design experiments, record results, and analyze data in an organized way. Benchling operates on a subscription-based model, offering various pricing tiers based on organizational size and feature needs, ensuring a steady revenue stream. The company differentiates itself by providing tailored enterprise solutions and additional services like training and support, aiming to enhance the efficiency of scientific research and accelerate the development of innovations in the life sciences sector.
Company Size
501-1,000
Company Stage
Series F
Total Funding
$400.7M
Headquarters
San Francisco, California
Founded
2012
Help us improve and share your feedback! Did you find this helpful?
Four months of fully paid parental leave
401(k) plan
Remote working stipend
Yearly company-wide retreat
Monthly gym and wellness stipend
Commuter benefits
100% premiums covered for health, dental, and vision
Weekly company social events
Flexible PTO and company-wide winter holiday shutdown
We’re excited to announce Benchling’s acquisition of PipeBio, a leader in high-throughput bioinformatics analysis, to drive biologics discovery.
The collaboration is expected to improve the efficiency of the discovery process by combining PipeBio's advanced sequence analysis tools with Benchling's established software ecosystem.
In a significant move to streamline its R&D operations, Novonesis, a global leader in biosolutions, has selected Benchling as its digital platform to enhance the discovery, development, and testing processes across its scientific teams.
Under his leadership, Benchling expanded its customer base to over 1,000 companies, including more than 20 of the top 50 global biopharma companies and hundreds of emerging, growth, and enterprise biotechnology firms.
With heaps of creativity and now a new collaboration with H. Moser & Cie., Benc is starting to leave his "underdog" status behind.
Sanofi forms cloud partnership with Benchling.
R&D Cloud provider Benchling Sanofi , which will use its cloud services has partnered with French global pharmaceutical company across more than 1,500 scientists from 30 teams.Benchling software that powers many biotech startups and more than half of the top 50 global biopharma companies. Over 200,000 scientists rely on the Benchling R&D Cloud as their central source of truth for scientific data, analysis and collaboration.Sanofi is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo.Benchling is working with Sanofi to transition from legacy R&D systems to a digital platform through Benchling R&D Cloud; this is an integral process to enable Sanofi's AI-powered R&D ambition. As a result of the partnership, its R&D teams are able to scale and accelerate groundbreaking research processes in just hours instead of weeks.Benchling R&D Cloud is used by teams across Sanofi, including early discovery-omics such as precision oncology, core therapeutic pipeline teams including novel modalities like mRNA, all the way up the lifecycle to translational teams. Through Benchling's R&D Cloud, complex data from various departments at Sanofi is aggregated, enabling better decision-making, analytics, and collaboration. This real-time visibility into standardized data across teams gives Sanofi high-quality inputs to gain new insight faster."Sanofi is paving the way for a new era of biotechnology, where every stage of R&D is faster, smarter, and more automated," said Sajith Wickramasekara, CEO and co-founder Benchling
Over 30 global teams and 1,500 scientists at Sanofi use Benchling for R&D data capture and analysisSAN FRANCISCO, June 11, 2024 /PRNewswire/ -- Benchling, the R&D Cloud powering the biotech industry, today announced that global pharmaceutical company Sanofi is using Benchling across more than 1,500 scientists from 30 teams.Benchling is working with Sanofi to transition from legacy R&D systems to a digital platform through Benchling R&D Cloud; this is an integral process to enable Sanofi's AI-powered R&D ambition. As a result of Sanofi's digital and AI leadership, R&D teams are able to scale and accelerate groundbreaking research processes in just hours instead of weeks."Sanofi is paving the way for a new era of biotechnology, where every stage of R&D is faster, smarter, and more automated," said Sajith Wickramasekara, CEO and co-founder Benchling. "Sanofi's adoption of Benchling unlocks their ability to harness AI. With our R&D Cloud, Sanofi scientists can do their best work and accelerate timelines for life-changing medicines."Benchling R&D Cloud is used by teams across Sanofi, including early discovery-omics such as precision oncology, core therapeutic pipeline teams including novel modalities like mRNA, all the way up the lifecycle to translational teams. Through Benchling's R&D Cloud, complex data from various departments at Sanofi is aggregated, enabling better decision-making, analytics, and collaboration. This real-time visibility into standardized data across teams gives Sanofi high-quality inputs to gain new insight faster.About BenchlingBenchling creates the software that powers the biotechnology industry, serving cutting-edge start-ups and more than half of the top 50 global biopharma companies
San Francisco, USA Zurich, Switzerland. April 23, 2024. Today Benchling announced that Zealand Pharma A/S, (“Zealand”) a biotechnology company focused on the discovery and development of peptide-based medicines, has selected the Benchling RD Cloud as its central source of truth for scientific data, collaboration, and insights. Teams across Zealand will use the Benchling RD Cloud to capture, analyze, and share stability data internally and with their external contract manufacturing organization (CMO) partners, in compliance with GxP. “Our research progresses quickly, every action needs to be traceable and verifiable. Scientists and partners can’t be slowed down by siloed systems or a lack of consistent data,” said Ludo Otterbein, Head of IT at Zealand Pharma
Fast-growing Danish biotech adopts Benchling R&D Cloud for greater data accessibility, collaboration, and complianceSAN FRANCISCO and ZURICH, April 23, 2024 /PRNewswire/ -- Today Benchling announced that Zealand Pharma A/S, ("Zealand") a biotechnology company focused on the discovery and development of peptide-based medicines, has selected the Benchling R&D Cloud as its central source of truth for scientific data, collaboration, and insights. Teams across Zealand will use the Benchling R&D Cloud to capture, analyze, and share stability data internally and with their external contract manufacturing organization (CMO) partners, in compliance with GxP."Our research progresses quickly, every action needs to be traceable and verifiable. Scientists and partners can't be slowed down by siloed systems or a lack of consistent data," said Ludo Otterbein, Head of IT at Zealand Pharma. "Connecting the lab and automating data capture and sharing through technology is a critical priority. Benchling will provide Zealand with the digital data foundation that helps us safely and confidently scale new use cases and partners."Zealand is a Nasdaq Copenhagen 25 (OMX C25) Index company with a mission to change lives with next generation peptide medicines, focusing on metabolic diseases such as obesity. The company works across many CMOs and partners and requires real-time access to data and secure, compliant information exchange